AlloVir, Inc. (Nasdaq: ALVR), relating to its proposed merger with Kalaris Therapeutics. Under the terms of the agreement, AlloVir will acquire 100% of the outstanding equity interest of Kalaris. Upon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback